Search by Categories
- Insights
- Rare Disease
- Oncology
- Cell and Gene Therapy
- Medical Devices
- Consulting
- News & Analysis
- Therapeutic Areas
Our expertise in the industry
Roche Set to Compete With Biogen and Novartis in the SMA Market With its First Oral Therapy The US FDA has recommended the use of Evrysdi (risdiplam), a candidate of Genentech, a Roche c...
Spinal Muscular Atrophy is a rare and the second most fatal autosomal recessive genetic disorder with an incidence of 1 in 6000 to 1 in 10,000 births. Globally talking, SMA prevalence was reported...
The U.S. FDA recently approved the much talked about Novartis’s drug Zolgensma for treating a life-threatening condition Spinal Muscular Atrophy (SMA). SMA is a neuromuscular disorder that w...
SMA (Spinal Muscular Atrophy) - a disease that takes away the physical strength of people by affecting the motor nerve cells in the spinal cord, also people have a problem in walking, eating, or ...
Spinal muscular atrophy (SMA) being a rare genetic neuromuscular disorder results in progressive muscle weakness and atrophy. It affects the part of the nervous system that controls voluntary musc...
Spinal Muscular Atrophy (SMA) is a genetic disorder that affects the part of the nervous system which controls the voluntary movement of limbs and muscles. SMA results in the loss of motor neurons...
Human Immunodeficiency Virus or HIV is a species of Lentivirus (genus of retrovirus) th...
Progress is driven by innovation. When it comes to developing novel medications and the...
The HIV-1 treatment market for naïve and experienced patients is evolving consistently....
The Pharmaceuticals segment of the Healthcare Industry has a significant market across ...
Von Willebrand disease is a type of blood disorder that causes the blood to clot improp...
Hear from our subject-matter experts and in-house KOL’s on Pharma and Healthcare market trends.
